In 2021, the Total Profit of China's Pharmaceutical Industry will Exceed 700 Billion Yuan, a Year-on-year Increase of 67.3%
On May 10, at the press conference of the National Development and Reform Commission on the "14th Five-Year Plan for Bioeconomic Development", Zhou Jian, deputy director of the Consumer Products Industry Department of the Ministry of Industry and Information Technology, introduced that in 2021, the main economic indicators of my country's pharmaceutical industry will show rapid growth.
Specifically, in 2021, the added value of the pharmaceutical industry will increase by 23.1% year-on-year, and the growth rate will increase by 15.3 percentage points over the same period of the previous year, which is 13.5 percentage points higher than the overall growth rate of all industries. The proportion of the added value of the pharmaceutical industry in the total industrial added value continued to rise, accounting for 4.1%, and its role in stabilizing industrial economic growth was further enhanced. The operating income was 3,370.75 billion yuan, a cumulative year-on-year increase of 18.7%, an increase of 11.4 percentage points over the same period of the previous year, and the growth rate reached a new high in the past five years. The total profit achieved was 708.75 billion yuan, a year-on-year increase of 67.3%.
Looking for chemical products? Let suppliers reach out to you!
2026-06-25
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
The relationship between Digital Transformation and Work- Life Balance in the Egyptian Pharmaceutical Industry
-
What Does the Future Hold for the Anti-Obesity Drug Market in 2024?
-
Hengrui entered the top 20 for the first time. How big is the gap between Chinese and American pharmaceutical companies?
-
The State Food and Drug Administration accepted the marketing application of Ditze Pharma suvortinib
-
Jimin's innovative polycystic kidney disease innovative drug was approved by the FDA for clinical trials
-
Another giant may be broken up
-
NASH is on the verge of a new drug, and the 40-year black hole is finally shining a light
-
Novo Nordisk Shanghai and ShanghaiPharmaceutical Holdings sign a contract to make another breakthrough incooperation
-
Zebutinib recommended as 'Class I priority' in international guidelines
-
FDA approves 'ibrutinib' for chronic graft-versus-host disease in children 1 year and older
Recommend Reading
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
Active Trading Drives Price Increases, Melamine Market Breaks Out of Sideways Trend
-
Supply Tight, Shandong Normal Butanol Market Edges Up
-
Cyclohexane Market Maintains Stable Operation
-
Short-term Ethylene Glycol is Likely to Experience a Strong Sideways Consolidation
-
Mine Shutdown Drives Up Lithium Carbonate Prices